CY1118413T1 - Κρυσταλλικη μορφη πεμιρολαστης - Google Patents

Κρυσταλλικη μορφη πεμιρολαστης

Info

Publication number
CY1118413T1
CY1118413T1 CY20171100039T CY171100039T CY1118413T1 CY 1118413 T1 CY1118413 T1 CY 1118413T1 CY 20171100039 T CY20171100039 T CY 20171100039T CY 171100039 T CY171100039 T CY 171100039T CY 1118413 T1 CY1118413 T1 CY 1118413T1
Authority
CY
Cyprus
Prior art keywords
cooker
crystal former
former
crystal
pamirolast
Prior art date
Application number
CY20171100039T
Other languages
Greek (el)
English (en)
Inventor
Anett Perlberg
Martin Viertelhaus
Ulrika Rosenström
Karol Horvath
Original Assignee
Rspr Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rspr Pharma Ab filed Critical Rspr Pharma Ab
Publication of CY1118413T1 publication Critical patent/CY1118413T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Secondary Cells (AREA)
  • Dental Preparations (AREA)
CY20171100039T 2009-06-16 2017-01-11 Κρυσταλλικη μορφη πεμιρολαστης CY1118413T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18734809P 2009-06-16 2009-06-16
US18735509P 2009-06-16 2009-06-16
PCT/GB2010/001168 WO2010146348A2 (en) 2009-06-16 2010-06-15 New crystalline form of pemirolast

Publications (1)

Publication Number Publication Date
CY1118413T1 true CY1118413T1 (el) 2017-06-28

Family

ID=43264726

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100039T CY1118413T1 (el) 2009-06-16 2017-01-11 Κρυσταλλικη μορφη πεμιρολαστης

Country Status (31)

Country Link
US (3) US20120157415A1 (enExample)
EP (2) EP2443120B1 (enExample)
JP (2) JP5722317B2 (enExample)
KR (2) KR20170049645A (enExample)
CN (1) CN102596202B (enExample)
AR (1) AR077915A1 (enExample)
AU (1) AU2010261540B2 (enExample)
BR (1) BRPI1015559A2 (enExample)
CA (1) CA2765408A1 (enExample)
CY (1) CY1118413T1 (enExample)
DK (1) DK2443120T3 (enExample)
EA (1) EA025865B1 (enExample)
ES (1) ES2613059T3 (enExample)
HR (1) HRP20170023T1 (enExample)
HU (1) HUE032978T2 (enExample)
IL (1) IL216670A (enExample)
LT (1) LT2443120T (enExample)
ME (1) ME02685B (enExample)
MX (1) MX2011013676A (enExample)
NZ (1) NZ596747A (enExample)
PL (1) PL2443120T3 (enExample)
PT (1) PT2443120T (enExample)
RS (1) RS55558B1 (enExample)
SA (1) SA114350792B1 (enExample)
SG (1) SG176295A1 (enExample)
SI (1) SI2443120T1 (enExample)
SM (2) SMT201700085T1 (enExample)
TW (1) TWI504599B (enExample)
UY (1) UY32711A (enExample)
WO (2) WO2010146348A2 (enExample)
ZA (1) ZA201109045B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2780382A1 (en) * 2009-11-13 2011-05-19 Cardoz Ab Pemirolast for the treatment of systemic low grade inflammation
EP3978002A1 (en) * 2013-03-09 2022-04-06 Chiesi Farmaceutici S.p.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20160243122A1 (en) 2014-10-23 2016-08-25 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
AU2017340594B2 (en) * 2016-10-03 2020-09-10 Brivention Pharmaceutical (Shanghai) Inc. Composition comprising combination of TRH analog with arundic acid, and pharmaceutically acceptable salt of arundic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
JP2504788B2 (ja) 1987-11-10 1996-06-05 東京田辺製薬株式会社 9−メチル−3−(1H−テトラゾ―ル−5−イル)−4H−ピリド[1,2−a]ピリミジン−4−オンカリウム塩の水性製剤
JP2837449B2 (ja) * 1989-08-11 1998-12-16 東京田辺製薬株式会社 ピリド[1,2―a]ピリミジン誘導体の製造法
ITMI20011764A1 (it) 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
BRPI0615775B1 (pt) 2005-09-16 2021-08-10 Daiichi Sankyo Company, Limited Processos para a produção de compostos derivados de diamida oticamente ativos
EA200900815A1 (ru) * 2006-12-18 2009-12-30 Кардос Аб Новая комбинация, предназначенная для лечения воспалительных нарушений
US20100168137A1 (en) * 2006-12-20 2010-07-01 Johan Raud Combination for use in the treatment of inflammatory disorders

Also Published As

Publication number Publication date
WO2010146341A2 (en) 2010-12-23
WO2010146348A2 (en) 2010-12-23
IL216670A0 (en) 2012-02-29
CN102596202A (zh) 2012-07-18
SA114350792B1 (ar) 2015-11-10
WO2010146348A9 (en) 2012-05-03
EA025865B1 (ru) 2017-02-28
ZA201109045B (en) 2013-05-29
WO2010146341A3 (en) 2011-03-03
US20120157415A1 (en) 2012-06-21
JP5722317B2 (ja) 2015-05-20
KR20170049645A (ko) 2017-05-10
TWI504599B (zh) 2015-10-21
JP2015120750A (ja) 2015-07-02
EP2443120B1 (en) 2016-11-02
DK2443120T3 (en) 2017-01-09
JP2012530118A (ja) 2012-11-29
LT2443120T (lt) 2017-02-10
SG176295A1 (en) 2012-01-30
HRP20170023T1 (hr) 2017-03-10
WO2010146348A3 (en) 2011-03-03
SI2443120T1 (sl) 2017-04-26
SMT201700085T1 (it) 2017-03-08
US20140329839A1 (en) 2014-11-06
NZ596747A (en) 2014-01-31
AU2010261540A2 (en) 2012-01-19
AR077915A1 (es) 2011-10-05
IL216670A (en) 2017-02-28
PT2443120T (pt) 2017-02-08
BRPI1015559A2 (pt) 2016-04-26
HUE032978T2 (hu) 2017-11-28
CN102596202B (zh) 2015-01-21
RS55558B1 (sr) 2017-05-31
TW201100422A (en) 2011-01-01
US20170202839A1 (en) 2017-07-20
CA2765408A1 (en) 2010-12-23
UY32711A (es) 2011-01-31
AU2010261540A1 (en) 2012-01-19
AU2010261540B2 (en) 2016-04-14
ME02685B (me) 2017-06-20
EP2443120A2 (en) 2012-04-25
KR20120032530A (ko) 2012-04-05
EA201200017A1 (ru) 2013-10-30
US9006431B2 (en) 2015-04-14
PL2443120T3 (pl) 2017-04-28
SMT201700085B (it) 2017-03-08
ES2613059T3 (es) 2017-05-22
MX2011013676A (es) 2012-02-08
EP3141549A1 (en) 2017-03-15

Similar Documents

Publication Publication Date Title
FIC20230032I1 (fi) Pegunigalsidaasi alfa
CYD2019001I2 (el) Διαμορφωση της εκφρασης τρανσθυρετινης
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
EP2563776A4 (en) COMPOUNDS AS MODULATORS OF INTRA CELLULAR CALCIUM
DK2534173T3 (da) Manipulerede spaltnings-halvdomæner
BRPI1010795A2 (pt) compostos antivirais
BR112013028512A2 (pt) cápsula
PT2623498E (pt) Sal de sódio de 6-fluoro-3-hidroxi-2-pirazino-carboxamida
HUE055375T2 (hu) Fluorszulfonil-imid alkálifémsója
BR112013023523A2 (pt) intensificador de pressão submarino
BR112013025755A2 (pt) aparelho de guincho
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
HRP20181695T1 (hr) Kristalni oblik inhibitora benzilbenzena sglt2
EP2474262A4 (en) STEREOSCOPIC ENDOSCOPE
DK3378856T3 (da) Krystallinske methylthioniniumchlorid-hydrater
BR112013011510A2 (pt) âncora submarina
PT2640718T (pt) 1h-pirazole-5-olato de sódio substituído
CL2009001973S1 (es) Mostrador.
ITMI20120351A1 (it) Procedimento per la produzione di bicarbonato di sodio
BR112013008116A2 (pt) cabeça de poço submarino.
MX2011013676A (es) Forma cristalina de pemirolast.
LT2600881T (lt) Natūralus medicinins junginys
FI20096192A0 (fi) Kohteen valaiseminen
FR2959346B1 (fr) Ventouse electromagnetique comportant une source lumineuse
ES2530436T3 (es) Combinación